American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

Besides diabetes, obesity is a major risk factor for hypertension and heart disease, creating what can only be described as a ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

During the conference, Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent, delivered a presentation highlighting ...

Ozempic and Wegovy have become popular options for people looking to lose weight, but there are some risks and side effects ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...